Compare Gilead Sciences, Inc. (GILD) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs RLX Technology Inc — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while RLX Technology Inc trades at $2.03 (market cap $2.46B). The key difference: Gilead Sciences, Inc. is far larger — about 66.5× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (4.98%). Which is the better fit depends on your goals.
| GILD | RLX | |
|---|---|---|
Market Cap | $163.51B | $2.46B |
Sector | Health | Technology |
52-Week High | $155.80 | $2.73 |
52-Week Low | $108.22 | $1.79 |
Enterprise Value | $178.05B | $1.09B |
Dividend Yield | 2.49% | 4.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RLX trades at $2.025, up 2.27% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. With a P/E of 18.37 and strong cash flow from operations of $1.10B in 2025, fundamentals show profitability but recent earnings underperformance warrants attention.
The outlook is mixed; RLX operates in a high-growth vaping market projected to reach $462bn by 2033, and it is debt-free with a cash-rich balance sheet. However, risks include regulatory pressures in China and consistent earnings misses. Analyst sentiment is neutral with a single hold rating, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
